滤泡调节性T细胞与β细胞自身免疫及1型糖尿病发生相关
该研究评估了1型糖尿病(T1D)、2型糖尿病(T2D)患者、T1D一级亲属及健康对照的外周血滤泡调节性T(Tfr)细胞,并在NOD小鼠和过继转移模型中验证。结果显示两组糖尿病患者Tfr细胞均显著减少,Tfr细胞频率与T1D患者自身抗体阳性数目及谷氨酸脱羧酶抗体滴度相关,随访1年后进一步下降,且Tfr细胞与NOD小鼠及过继转移模型中糖尿病发生相关。结论提示Tfr细胞缺陷可能参与T1D发病,Tfr细胞治疗具有潜在价值。
要点
- T1D和T2D患者外周血Tfr细胞均显著减少,但与空腹C肽及C肽曲线下面积的关联在两类糖尿病中不同。
- T1D患者Tfr细胞频率与自身抗体阳性数目及谷氨酸脱羧酶抗体滴度相关,随访1年后显著下降。
- NOD小鼠和过继转移模型中Tfr细胞与糖尿病发生相关,提示Tfr细胞缺陷可能参与T1D发病。
核心结论
- Tfr细胞缺陷可能参与1型糖尿病的发病机制。
- Tfr细胞治疗对1型糖尿病具有潜在价值,调节这些细胞可能增强保护性免疫以抑制自身免疫性糖尿病。
研究设计与样本
- 研究比较了1型糖尿病患者、2型糖尿病患者、1型糖尿病患者一级亲属及健康对照的外周血Tfr细胞表达与功能变化。
- 研究还在非肥胖糖尿病(NOD)小鼠和过继转移模型中探讨了Tfr细胞对疾病发生的影响。
主要发现
- Tfr细胞在1型糖尿病和2型糖尿病两组患者中均显著减少,但与空腹C肽及血C肽曲线下面积的关联在两组中不同。
- 1型糖尿病患者中Tfr细胞频率与自身抗体阳性数目及谷氨酸脱羧酶抗体滴度相关。
- 1型糖尿病患者随访1年后Tfr细胞显著下降。
- 在4例接受利妥昔单抗治疗的1型糖尿病患者中观察了Tfr细胞,治疗后3例患者CXCR5+程序性死亡1+Tfr细胞频率下降、CXCR5+诱导性共刺激分子+Tfr细胞频率上升。
- NOD小鼠和过继转移模型中Tfr细胞与糖尿病发生相关。
临床怎么用
- Tfr细胞频率及自身抗体相关变化可能作为1型糖尿病β细胞自身免疫的监测指标,但尚需进一步验证。
- Tfr细胞调节为1型糖尿病免疫治疗提供了潜在方向,目前仍处于研究阶段。
局限性
- 原文未明确报告研究样本量、随访时长(除1年外)及统计显著性数值。
- 利妥昔单抗治疗后Tfr细胞变化的观察仅基于4例患者,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Impaired follicular regulatory T (Tfr) cells enhance T follicular helper cells activity, resulting in the expansion of autoreactive B cells and autoantibody production. However, the role of Tfr cells in the pathogenesis of type 1 diabetes (T1D) is unclear. DESIGN: We evaluated the expression and changes in function of circulating Tfr cells by studying patients with T1D alongside those with type 2 diabetes (T2D), first-degree relatives of T1D patients, and healthy controls. We also investigated the effects of Tfr cells on disease development in nonobese diabetic (NOD) mice and in an adoptive transfer model. RESULTS: Tfr cells were significantly decreased in both patient groups. However, they showed different correlations with fasting C-peptide (C-P) and the area under the curve of blood C-P in patients with T1D and T2D. The frequency of Tfr cells was associated with the number of positive autoantibodies and the titer of glutamic acid decarboxylase autoantibody in T1D patients. Furthermore, Tfr cells decreased significantly after 1 year of follow-up. We also observed Tfr cells in four T1D patients treated with rituximab. After rituximab therapy, the frequency of C-X-C motif chemokine receptor 5 (CXCR5)+ programmed death 1+ Tfr cells was decreased and of CXCR5+ inducible costimulator+ Tfr cells was increased in three patients. We also found that Tfr cells were associated with the development of diabetes in NOD mice and an adoptive transfer model. CONCLUSIONS: Tfr cell deficiency could be involved in the pathogenesis of T1D. Therapy with Tfr cells has potential value for T1D. Modulation of these cells may enhance protective immunity to inhibit autoimmune diabetes.
引用
- Xu X, Shen M, Zhao R, et al. Follicular Regulatory T Cells Are Associated With β-Cell Autoimmunity and the Development of Type 1 Diabetes. J Clin Endocrinol Metab. 2019. PMID: 31095320. doi:10.1210/jc.2019-00093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。